Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression

C Laronga1, H Y Yang, C Neal

  • 1Departments of Surgical Oncology/Molecular and Cellular Oncology and the Breast Cancer Research Program, the University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

Insights

14-3-3 sigma protein, a cell cycle regulator, was identified through its association with cyclin-dependent kinase 2 (CDK2). Its overexpression inhibits cell cycle progression and proliferation, suggesting a role in preventing breast tumor growth.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • 14-3-3 sigma is involved in p53-mediated cell cycle arrest.
  • It shares binding motifs with known cell cycle regulators.

Purpose of the Study:

  • To clone 14-3-3 sigma using expression cloning.
  • To investigate its role in cell cycle regulation and breast cancer.

Main Methods:

  • Expression cloning based on cyclin-dependent kinase 2 (CDK2) association.
  • In vitro and in vivo association studies with cyclin-CDK complexes.
  • Overexpression studies in breast cancer cell lines.

Main Results:

  • 14-3-3 sigma was cloned via CDK2 association.
  • It associates with cyclin-CDK complexes.
  • Overexpression inhibits cyclin-CDK activity, cell cycle entry, proliferation, and anchorage-independent growth in breast cancer cells.

Conclusions:

  • 14-3-3 sigma acts as a negative regulator of cell cycle progression.
  • It plays a significant role in inhibiting breast tumor cell growth.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...